

Key word index of Volume 252 • 2002

- Acute phase response 110
 ADHD 219
 Affective disorder 49
 Affective symptoms 44
 Agression 155
 Alcohol 197
 Alcoholism 124, 155, 197
 Alzheimer's disease 63, 93
 Anterior cingulate gyrus 268
 Antidepressant 105
 Antipsychotic agents 294
 Antisocial personality disorder 8
 Anxiety 68, 81, 93
 ApoE 235
 Asymmetry 1, 268
 Attention deficit hyperactivity disorder in adults (ADHD) 177
 Atypical depression 135, 288
 Atypical neuroleptic 76
- Behçet's disease 44
 Bipolar disorder 110
 Bipolar disorders 24
 Bipolar II disorder 135, 288
 Blink reflex 141
 Brain tumor 299
- Cannabis 86
 Carbamazepine 197
 Categories 12
 Cerebrospinal fluid 120
 Cholesterol 110
 Chromosome 6 232
 Citalopram 105
 Clomipramine 105, 166, 172
 Cognition 24
 Cognitive models 240
 Cognitive-behavioral treatment (CBT) 177
 Combat 68
 Comorbidity 147, 201
 Conduct disorder 8
 Controlled clinical trial 76
 Coping 201
 Corticosteroids 44
 Cortisol 161, 172
 Criminal offending 8
- Days of the week 28
 Deficit schizophrenia 214
 Dementia 235
 Depression 28, 81, 166, 172, 201, 210
 Depressive disorder 240
 Diagnosis 135
 Diagnostic 99
 Dialectic behavioral therapy (DBT) 177
 Dimensions 12
 Divided attention 210
 Doctor-patient communication 19
 Dopamine 130
 DSM-IV 135, 288
 DST 161
 Duration of illness 115
 Duration of untreated psychosis 226
- Early intervention 115
 ECT 172
- Electroconvulsive therapy 166, 250
 Ethnic differences 232
 Exploratory eye movements 255
 Eye movements 49
 Eye tracking dysfunction 49
 Eye-mark recorder 255
- 5-HIAA 38
 Factor analysis 12, 19
 Fall-winter depression 54
 Familial aggregation 93
 Family study 93
 First admission 226
 First episode schizophrenia 262
 Fixation point 255
 Follow-up 262
 FTD 235
- G proteins 214
 G308A polymorphism 232
 Gender 201
 General medicine 99
 Grey matter 120
- Haloperidol 166, 172
 HDL 63
 Helplessness 240
 Hopelessness 240
 HVA 38
 Hypercholesterolaemia 294
 Hyperglycaemia 294
 Hypertriglyceridaemia 294
- Impulsivity 155
 Infusion 105
 Insomnia 99
- Latent class analysis 12
- Magnetic resonance imaging 120, 268
 Major depression 93, 250
 Mental illness 278
 MHPG 38
 Mixed manic states 110
 Monthly distribution 28
 Mood reactivity 135
 Mortality 8
 MR 235
 Multimorbidity 147
 Musical hallucinations 299
- Negative symptoms 214
 Neopterin 161
 Neurobiological correlates 240
 Neurocognition 33
 Neurocognitive deterioration 33
 Neurodegeneration 33
 Neurodevelopment 33
 Neuroimaging 68
 Neuropsychological functions 262
 Nondeficit schizophrenia 214
 Norepinephrine 130
- Outcome 226
 Outpatient detoxification 197
 Overeating 288
 Oversleeping 288
- P300 1
 Panic disorder 210
 Paraoxonase 63
 Patient satisfaction 19
 Periodic leg movement 124
 Personality 130
 Pharmacokinetic 76
 Pharmacotherapy 197
 Polysomnography 185
 Pons 44
 Positron emission tomography 68
 Pramipexole 185
 Premorbid functioning 226
 Prepulse-inhibition 141
 Prevalence 201
 Prolactin 166, 172
 Psychoeducation 115
 Psychometry 185
 Psychopathology 86
 Psychosis 12, 93
 Psychotherapy 177
 PTSD 161
 Public attitudes 278
- Quality of life 201
 Questionnaire 19
- Regional cerebral blood flow 68
 Relapse 124
 Restless legs syndrome 185
 Risk factors 93
- SAD 54
 Savoxepine 76
 Scan paths 255
 Schizophrenia 1, 24, 33, 49, 86, 115, 120, 141, 226, 232, 255, 268, 278
 Schizotypal disorder 268
 Seashore test 299
 Season of birth 130
 Seasonal affective disorder 54
 Seasonality 54
 Selective attention 210
 Self-medication 86
 Serotonin 130
 Serum cholesterol 8, 38
 Severity 147
 Skills training 177
 Sleep 124
 Sleep quality 185
 Smooth pursuit eye movement dysfunction 49
 Somatoform disorder 93
 SPECT 219
 SPM 219
 SSRI 105
 Startle reflex 141
 Stigma 278
 Subjective experiences 24
 Substance use disorder 81
 Suicidal thoughts 81
 Suicide 28, 110
 Suicide attempt 38, 155
 Suicide method 130
 Symmetry 235
- Temporal lobe 1, 120

Tiapride	197	Unidimensional construct	19	Weight	294
Training	99	Vascular dementia	63	White matter	120
Transcranial magnetic stimulation	250	Viloxazine	105	Women	81
Treatment	99	Vulnerability	86		
Tumor necrosis factor-alpha	232				